The objective was to evaluate the effect of inhaled corticosteroids on disease progression in smokers with moderate to severe chronic obstructive pulmonary disease (COPD), as assessed by annual computed tomography (CT) using lung density (LD) measurements. Two hundred and fifty-four current smokers with COPD were randomised to treatment with either an inhaled corticosteroids (ICS), budesonide 400 μ g bid, or placebo. COPD was defined as FEV1 ≤ 70 pred, FEV1/FVC ≤ 60 and no reversibility to β2-agonists and oral corticosteroids. The patients were followed for 24 years with biannual spirometry and annual CT and comprehensive lung function tests (LFT). CT images were analysed using Pulmo-CMS software. LD was derived from a pixel-density histogram of the whole lung as the 15thpercentile density (PD15) and the relative area of emphysema at a threshold of -910 Hounsfield units (RA-910), and both were volume-adjusted to predicted total lung capacity. At baseline, mean age was 64 years and 64 years; mean number of pack-years was 56 and 56; mean FEV1 was 1.53 L (51 pred) and 1.53 L (53 pred); mean PD15 was 103 g/L and 104 g/L; and mean RA-910 was 14 and 13, respectively, for the budesonide and placebo groups. The annual fall in PD15 was -1.12 g/L in the budesonide group and -1.81 g/L in the placebo group (p 0.09); the annual increase in RA910 was 0.4 in the budesonide group and 1.1 in the placebo group (p 0.02). There was no difference in annual decline in FEV1 between ICS (-54 mL) and placebo (-56 mL) (p 0.89). Long-term budesonide inhalation shows a non-significant trend towards reducing the progression of emphysema as determined by the CT-derived 15th percentile lung density from annual CT scans in current smokers with moderate to severe COPD.
|Tidsskrift||COPD: Journal of Chronic Obstructive Pulmonary Disease|
|Status||Udgivet - 4 nov. 2009|